Actinium Pharmaceuticals, Inc. (ATNM)
1.05
-0.05
(-4.55%)
USD |
NYAM |
Aug 24, 16:00
1.075
+0.02
(+2.38%)
Pre-Market: 09:10
Actinium Pharmaceuticals Enterprise Value : -2.118M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -2.118M |
| August 21, 2026 | -0.5465M |
| August 20, 2026 | 0.0824M |
| August 19, 2026 | 0.3968M |
| August 18, 2026 | -1.175M |
| August 17, 2026 | -2.118M |
| August 14, 2026 | -2.433M |
| August 13, 2026 | -4.826M |
| August 12, 2026 | -9.316M |
| August 11, 2026 | -10.20M |
| August 10, 2026 | -10.92M |
| August 07, 2026 | -10.06M |
| August 06, 2026 | -10.39M |
| August 05, 2026 | -11.59M |
| August 04, 2026 | -9.664M |
| August 03, 2026 | -9.617M |
| July 31, 2026 | -8.819M |
| July 30, 2026 | -8.816M |
| July 29, 2026 | -8.819M |
| July 28, 2026 | -7.888M |
| July 27, 2026 | -8.268M |
| July 24, 2026 | -8.092M |
| July 23, 2026 | -7.118M |
| July 22, 2026 | -6.835M |
| July 21, 2026 | -6.835M |
| Date | Value |
|---|---|
| July 20, 2026 | -7.369M |
| July 17, 2026 | -6.146M |
| July 16, 2026 | -7.149M |
| July 15, 2026 | -6.209M |
| July 14, 2026 | -6.989M |
| July 13, 2026 | -6.678M |
| July 10, 2026 | -5.892M |
| July 09, 2026 | -4.634M |
| July 08, 2026 | -4.634M |
| July 07, 2026 | -2.118M |
| July 06, 2026 | -4.917M |
| July 02, 2026 | -4.288M |
| July 01, 2026 | -4.326M |
| June 30, 2026 | -4.319M |
| June 29, 2026 | -9.552M |
| June 26, 2026 | -9.552M |
| June 25, 2026 | -10.81M |
| June 24, 2026 | -8.924M |
| June 23, 2026 | -8.610M |
| June 22, 2026 | -8.297M |
| June 18, 2026 | -8.297M |
| June 17, 2026 | -8.610M |
| June 16, 2026 | -9.866M |
| June 15, 2026 | -9.238M |
| June 12, 2026 | -8.924M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
| Savara, Inc. | 999.39M |
| Vericel Corp. | 2.097B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 27.90M |
| Revenue (Quarterly) | 35.00M |
| Total Expenses (Quarterly) | 7.099M |
| EPS Diluted (Quarterly) | 0.8884 |
| Gross Profit Margin (Quarterly) | 98.77% |
| Profit Margin (Quarterly) | 79.72% |
| Earnings Yield | 33.97% |
| Operating Earnings Yield | 29.11% |
| Normalized Earnings Yield | 33.97 |